Annexon, Inc.
A clinical-stage biopharmaceutical company developing therapies that target the complement system, the part of the immune system that helps clear damaged cells and defend against infection. Its lead programs focus on treating autoimmune and inflammatory diseases of the nervous system and eye. The company was founded in 2011 and is headquartered in Brisbane, California.
Bought 8.59M
Bought 400.0K
Bought 300.0K
Bought 200.0K
Bought 700.0K
Granted 323.5K · Bought 60.0K · Sold 47.5K
Granted 250.9K · Sold 126.0K
Granted 187.3K · Sold 26.2K
Granted 146.5K · Sold 16.7K
Granted 199.3K · Bought 2.0K · Sold 43.7K
Granted 140.2K · Sold 16.6K
Bought 78.4K
Bought 33.0K
Granted 21.9K
Granted 16.5K · Sold 4.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Satter Muneer ADirector · 11 transactions | — | 28.98M | — | 8.59M | — |
| Koppel Adam +5 co-filers10% owner · 3 transactions | — | 5.76Mas of Jul 2020 | — | 400.0K | — |
| BCIP Life Sciences Associates, LP +3 co-filers10% owner · 1 transaction | — | 5.40Mas of May 2023 | — | 300.0K | — |
| Blackstone Clarus III L.L.C. +7 co-filers10% owner · 5 transactions | — | 2.73Mas of Jul 2020 | — | 200.0K | — |
| Green Jeremy +1 co-filer10% owner · 1 transaction | — | 1.60Mas of Jul 2020 | — | — | — |
| Deerfield Management Company, L.P. (Series C) +5 co-filersReporting owner · 4 transactions | — | 917.8Kas of Jul 2020 | — | 700.0K | — |
| Love DouglasPRESIDENT AND CEO, Director · 28 transactions | — | 351.6Kas of Feb 2025 | 323.5K | 60.0K | 47.5K |
| Yednock TedEVP & CHIEF INNOVATION OFFICER · 33 transactions | — | 184.8K | 250.9K | — | 126.0K |
| Overdorf MichaelEVP & CHIEF BUSINESS OFFICER · 17 transactions | — | 182.6K | 187.3K | — | 26.2K |
| Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER · 6 transactions | — | 180.1K | 146.5K | — | 16.7K |
| Lew JenniferEVP & CHIEF FINANCIAL OFFICER · 26 transactions | — | 170.7K | 199.3K | 2.0K | 43.7K |
| Dananberg JamieCHIEF MEDICAL OFFICER · 6 transactions | — | 123.6K | 140.2K | — | 16.6K |
| Carson William H.Director · 18 transactions | — | 78.4K | — | 78.4K | — |
| Choi JungDirector · 1 transaction | — | 33.0K | — | 33.0K | — |
| Mattheakis LarryEVP & Chief Scientific Officer · 3 transactions | — | 17.2Kas of Jul 2022 | 21.9K | — | — |
| Keswani SanjayEVP & Chief Medical Officer · 3 transactions | — | 12.5Kas of Feb 2022 | 16.5K | — | 4.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +10.08M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.